



Corporate Headquarters
9009 Carothers Parkway, Suite C-2
Franklin, Tennessee 37067

Investor Contacts:

Ron Scarboro

Chief Financial Officer

ronald.scarboro@medquist.com

(615) 798-4350

Tripp Sullivan

Corporate Communications, Inc.

tripp.sullivan@cci-ir.com

(615) 324-7335

Media Contact:

Thomas Mitchell

Director of Marketing

tmitchell@medquist.com

(615) 798-6630

MedQuist Holdings Inc. Announces Senior Management Team Additions to Lead the Integration of M*Modal

Franklin, TN, September 6, 2011 – MedQuist Holdings Inc. (NASDAQ: MEDH), a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, announced additions to the senior management team as a result of the merger with M*Modal.

The new additions to the team include Michael Finke as President, Juergen Fritsch as Chief Scientist, Detlef Koll as Chief Technology Officer and Ronald Scarboro as Chief Financial Officer. Mr. Scarboro is replacing Tony James, who has resigned to pursue an opportunity with a private healthcare company. Mr. James will stay until October 1, 2011, to assist with the transition.

Mr. Scarboro, who has been with the Company since August 15, 2011, as Senior Financial Executive, has 20 years of technology and healthcare industry experience in finance and accounting, investor relations and acquisitions. Most recently, he held the position of Chief Financial Officer, Strategic Diversification at Aetna, Inc. Prior to Aetna, Ron held executive positions in finance and strategic operations with Allscripts, Misys Healthcare, The Trizetto Group, Verian Technologies, A4 Health Systems and other companies. He holds a BA degree from North Carolina State University and is a Certified Public Accountant.

Mr. Finke, who was previously Chairman, CEO and Co-Founder of M*Modal, will lead the Company's strategic account development, joint innovation and collaboration with healthcare provider organizations, and partnerships with healthcare IT and services companies, as well as industry thought leadership. A respected technology leader in the field of conversational speech recognition and natural language understanding, Mr. Finke has led M*Modal from inception in 2001 to its industry leadership role and large scale adoption of its unique cloud based natural language understanding services. Prior to M*Modal, Mr. Finke served as Chief Technology Officer and a Co-Founder of Interactive Systems (ISI) and has held positions at IBM, the University of Karlsruhe and Carnegie Mellon University. He has published more than 30 articles and earned his B.Eng. and M.Eng. degrees in computer science from the University of Karlsruhe, Germany.

Dr. Fritsch was previously Chief Scientist and Co-Founder of M*Modal and will be responsible for core research and innovations. At M*Modal, he was instrumental in growing the company's IP portfolio and establishing its leadership role in the field of conversational speech understanding. Before founding M*Modal, he was one of the founders of ISI, where he served as Principal Research Scientist and was responsible for developing a next generation medical speech understanding system. Dr. Fritsch held research positions at the University of Karlsruhe

and at Carnegie Mellon University. He has published more than 20 papers and has been granted numerous patents on various speech recognition and natural language processing aspects relevant to the healthcare domain. He earned his M.Sc. and Ph.D. degrees in computer science from the University of Karlsruhe.

Mr. Koll, who was previously Chief Technology Officer and Co-Founder of M*Modal, will lead product development activities across the entire organization. At M*Modal, he was the driving force in the development of its Conversational Documentation Services platform and established M*Modal as the leading technology partner in the healthcare documentation space. Before founding M*Modal, he was a Co-Founder and Vice President for product development for ISI and served as Director of Speech Recognition Research at Lernout & Hauspie Speech Products. He has held research positions at Carnegie Mellon University and Advanced Telecommunications Research Laboratories in Kyoto, Japan. He earned his B.Eng. and M.Eng. degrees in computer science from the University of Karlsruhe.

Vern Davenport, Chairman and Chief Executive Officer of MedQuist Holdings, noted, "We've previously outlined aggressive plans to bring MedQuist and M*Modal together and align the resources between our two companies. The additions of Michael, Juergen, Detlef and Ron to the senior leadership team address the specific needs we identified in strategic account and partnerships, product development and organizational structure. I have tremendous respect for the talent and capabilities of this team. We all are aligned with executing on the opportunities we have to provide technology-enabled solutions to address the challenges facing our healthcare industry.

"We respect Tony's decision to return to the private arena and thank him for his many contributions to our company. He has played an integral role in our integration of Spheris and MedQuist as well as the acquisition of M*Modal. Ron had been brought on board to lead our internal strategic programs and organizational transformation. Ron will now be responsible for all financial operations of MedQuist, a role that he has executed well throughout his career."

About MedQuist Holdings

MedQuist Holdings is a leading provider of medical transcription services, and a leader in technology-enabled clinical documentation workflow. MedQuist's enterprise solutions – including mobile voice capture devices, speech recognition, Web-based workflow platforms, and global network of medical editors – help healthcare facilities improve patient care, increase physician satisfaction, and lower operational costs. For more information, please visit www.medquist.com.

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical, such as statements regarding the integration of M*Modal, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements only speak as of the date of this press release and MedQuist Holdings Inc. assumes no obligation to update the information included in this press release.

-MORE-

Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict, including, without limitation, specific factors discussed herein and in other releases and public filings made by MedQuist Holdings Inc. (including filings by MedQuist Holdings Inc. with the SEC). Although MedQuist Holdings believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, MedQuist Holdings also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

##